{
    "relation": [
        [
            "",
            "Cervarix Group",
            "Havrix Group"
        ],
        [
            "Description",
            "Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.",
            "Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm."
        ]
    ],
    "pageTitle": "Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00128661?sect=X315&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042985140.15/warc/CC-MAIN-20150728002305-00151-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 863609939,
    "recordOffset": 863585172,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. Population Description \u00a0 Hide Baseline Characteristics \u00a0 Baseline Characteristics \u00a0 Show Participant Flow \u00a0 Participant Flow Biological: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine Biological: hepatitis A inactivated virus vaccine Interventions: Cervical Cancer Precancerous Condition Conditions: Allocation:\u00a0Randomized; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Investigator,\u00a0Outcomes\u00a0Assessor); \u00a0 Primary\u00a0Purpose:\u00a0Prevention Study Design: Interventional Study Type:",
    "textAfterTable": "Total Total of all reporting groups Baseline Measures \u00a0 \u00a0 Cervarix Group \u00a0 \u00a0 Havrix Group \u00a0 \u00a0 Total \u00a0 Number of Participants \u00a0 [units:\u00a0participants] \u00a0 3727 \u00a0 \u00a0 3739 \u00a0 \u00a0 7466 \u00a0 Age \u00a0 [units:\u00a0Years] Mean (Standard Deviation) \u00a0 \u00a0 \u00a0 Years \u00a0 \u00a0 21.1 \u00a0(2.3) \u00a0 \u00a0 21.1 \u00a0(2.3) \u00a0 \u00a0 21.1 \u00a0(2.3) \u00a0 Gender \u00a0 [units:\u00a0Subjects] \u00a0 \u00a0 \u00a0 Female \u00a0 \u00a0 3727 \u00a0 \u00a0 3739 \u00a0 \u00a0 7466 \u00a0 Male",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}